Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $37.42 Average PT from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned a consensus rating of “Moderate Buy” from the seventeen analysts that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $37.57.

Several equities research analysts have recently weighed in on DNLI shares. Oppenheimer decreased their price objective on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a report on Monday. B. Riley reiterated a “buy” rating and set a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a research note on Friday, February 28th. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Monday, December 16th. Finally, JPMorgan Chase & Co. lowered their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th.

Insider Activity at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 29,266 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the sale, the chief executive officer now owns 260,721 shares in the company, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the sale, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,940 shares of company stock worth $973,442 over the last three months. 7.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC increased its stake in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock valued at $36,000 after purchasing an additional 1,516 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Denali Therapeutics in the fourth quarter valued at $62,000. Point72 Hong Kong Ltd acquired a new stake in Denali Therapeutics in the fourth quarter valued at $65,000. Quest Partners LLC purchased a new position in shares of Denali Therapeutics in the third quarter valued at $73,000. Finally, PNC Financial Services Group Inc. raised its stake in shares of Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after buying an additional 885 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Price Performance

Shares of DNLI opened at $16.30 on Friday. Denali Therapeutics has a 1-year low of $14.01 and a 1-year high of $33.33. The stock has a market cap of $2.35 billion, a PE ratio of -5.91 and a beta of 1.43. The firm has a fifty day moving average price of $21.07 and a 200 day moving average price of $24.46.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.08. As a group, equities analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.